What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered three times daily for up to 21 days (successive cohort).”In the company’s words, NCT05905328 on ClinicalTrials.gov
- Tested for
- Cytokine Release Syndrome
- Main trialPhase 1/2
- “This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with lymphoma or multiple myeloma who are scheduled to receive CAR T-cell therapy. The first phase of the study is open label with dose escalation. Participants will start taking CTO1681 either the day before starting lymphodepleting chemotherapy or just prior to receiving their CAR T-cell therapy, depending on their cohort assignment. In both cases participants will continue to take the study drug…”In the company’s words, NCT05905328 on ClinicalTrials.gov
Other drugs for Cytokine Release Syndrome
- GlofitamabRoche · Phase 2
- ObinutuzumabRoche · Phase 2
- PRS CK STORMPEACHES BIOTECH · Phase 1/2
- SL1CCHebei Senlang Biotech · Phase 1
- LinvoseltamabRegeneron · Marketed (Phase 4 trial)
Coming up1
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jun 2027 | Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026